Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
Key Highlights
- ➤Three nomlabofusp posters scheduled at ICAR 2026
- ➤Interim long-term daily nomlabofusp data to be presented
- ➤New plasma lipid analyses in Friedreich’s ataxia participants
- ➤New gene expression analyses assess response to nomlabofusp
BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich’s ataxia (FA) will be presented as part of three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) 2026 being held November 10–13, 2026, in Atlanta, Georgia.
Poster Presentation Details * Abstract Title: Long-Term Daily Nomlabofusp Administration in Patients with Friedreich’s Ataxia: Interim Observations from an Ongoing Open-Label Study
Get started
Create a free account to read the full story.